Jacobs Levy Equity Management Inc. Makes New $24.48 Million Investment in Insulet Corporation $PODD

Key Points

• Jacobs Levy Equity Management Inc. acquired a new position in Insulet Corporation (NASDAQ:PODD) during Q1, purchasing 93,210 shares valued at approximately $24.48 million.
• Several institutional investors significantly increased their stakes in Insulet during the first quarter, with GAMMA Investing LLC's position growing by a staggering 27,298.6%.
• Analysts have raised Insulet's price targets, with Goldman Sachs initiating coverage and setting a target of $380.00, indicating strong market confidence.

Jacobs Levy Equity Management Inc. purchased a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 93,210 shares of the medical instruments supplier's stock, valued at approximately $24,478,000. Jacobs Levy Equity Management Inc. owned 0.13% of Insulet as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. Captrust Financial Advisors grew its holdings in shares of Insulet by 24.1% in the fourth quarter. Captrust Financial Advisors now owns 2,185 shares of the medical instruments supplier's stock valued at $570,000 after acquiring an additional 425 shares in the last quarter. Brevan Howard Capital Management LP purchased a new stake in shares of Insulet during the fourth quarter worth $305,000. Driehaus Capital Management LLC lifted its position in shares of Insulet by 120.3% during the fourth quarter. Driehaus Capital Management LLC now owns 99,886 shares of the medical instruments supplier's stock worth $26,077,000 after acquiring an additional 54,539 shares in the last quarter. Frontier Capital Management Co. LLC lifted its position in shares of Insulet by 21.8% during the fourth quarter. Frontier Capital Management Co. LLC now owns 110,170 shares of the medical instruments supplier's stock worth $28,762,000 after acquiring an additional 19,692 shares in the last quarter. Finally, Ethic Inc. lifted its position in shares of Insulet by 44.3% during the fourth quarter. Ethic Inc. now owns 5,462 shares of the medical instruments supplier's stock worth $1,426,000 after acquiring an additional 1,678 shares in the last quarter.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on PODD shares. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Barclays upped their target price on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Citigroup restated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Canaccord Genuity Group increased their target price on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $335.12.

Insulet Trading Up 1.1%

PODD traded up $3.66 during midday trading on Thursday, reaching $341.27. 153,785 shares of the company's stock traded hands, compared to its average volume of 748,330. The firm has a fifty day moving average of $310.04 and a two-hundred day moving average of $291.09. The stock has a market capitalization of $24.02 billion, a price-to-earnings ratio of 103.92, a P/E/G ratio of 2.93 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 52 week low of $225.28 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the business posted $0.55 EPS. The company's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.